Postbiotic for synergistically improving blood glucose reducing capacity of D-psicose, composition and application

Abstract

The invention belongs to the technical field of microbial preparations, and particularly relates to a metagen for synergistically improving the hypoglycemic capacity of D-psicose, a composition and application. Specifically, the metagen is combined with the D-psicose, so that the hypoglycemic effect is remarkably improved. According to the D-psicose and the preparation method of the D-psicose, the metagen obtained through fermentation of the Lactobacillus gasseri co-1 has a synergistic effect with the D-psicose, so that the blood glucose metabolism can be more effectively regulated. In addition, the positive effect of the postbiotics in the aspect of intestinal health further enhances the overall hypoglycemic ability. The metabiotics can improve the intestinal environment related to metabolic diseases by enhancing the barrier function of the intestinal tract and regulating the flora of the intestinal tract. The multi-layer action mechanism not only is beneficial to the control of blood sugar, but also can improve the symptoms of the early stage of diabetes mellitus and effectively prevent or delay the development of diabetes mellitus, thereby having a good practical application value.

Description

Technical Field

[0001] The present invention belongs to the technical field of microbial preparations, and in particular relates to a postbiotic, a composition and an application thereof that synergistically improve the blood sugar-lowering ability of D-psicose. Background Art

[0002] Diabetes is a metabolic disease characterized by high blood sugar. Although its pathogenic factors and pathogenesis are complex and changeable, controlling sugar intake is still one of the most effective means to prevent and treat diabetes. Traditional sweeteners such as sucrose can effectively improve the flavor of food, but they are high in calories and have a high absorption rate, which can cause obesity, diabetes, cardiovascular disease and other diseases. Replacing sucrose with low blood sugar response sweeteners will become an effective way to prevent diseases such as diabetes. D-allulose is an important sweetener raw material and a commonly used prebiotic. Its energy value is 0.007 kcal / g. It is called an energy-free sweetener. It can effectively prevent the occurrence of obesity and prevent the increase of blood sugar. It has great application value in the prevention and treatment of metabolic diseases such as diabetes and obesity.

[0003] Postbiotics are a general term for the metabolites of probiotics after probiotics have been processed, including bacteria and metabolites. They have a strong regulatory effect on intestinal flora. According to clinical observations and research, postbiotics play a role in obesity and diabetes through multiple mechanisms. These pathways include increased energy consumption, adipocyte formation and differentiation, reduced food intake, changes in lipid and carbohydrate absorption and metabolism, and intestinal flora regulation.

[0004] Prebiotics and postbiotics are used to intervene in blood sugar as effective means of intestinal flora and intestinal function. Prebiotics can selectively stimulate the growth of beneficial bacteria, while postbiotics can enhance intestinal barrier function. The two may jointly improve glucose metabolism and insulin sensitivity through different mechanisms. However, there are almost no reports on the synergistic regulation of blood sugar by the prebiotic D-allulose and postbiotics, especially the synergistic effect of the two on improving blood sugar in patients with prediabetes. Summary of the invention

[0005] Based on the above-mentioned deficiencies in the prior art, the present invention provides a postbiotic, composition and application that synergistically improve the blood sugar lowering ability of D-psicose. Experiments have shown that the postbiotic prepared based on Lactobacillus gasseri of the present invention can effectively improve the blood sugar lowering ability of D-psicose, and the combination of the two can show a more effective blood sugar regulation effect. Based on the above research results, the present invention is completed.

[0006] In order to achieve the above technical objectives, the present invention relates to the following technical solutions: The first aspect of the present invention provides the use of postbiotics in preparing a product that improves the blood sugar lowering ability of D-psicose; Wherein, the postbiotics include inactivated Lactobacillus gasseri ( lactobacillus gasseri )co-1; The Lactobacillus gasseri ( lactobacillus gasseri )co-1, deposited in China Center for Type Culture Collection (Address: Wuhan University, Luojia Mountain, Wuchang, Wuhan City, Hubei Province), the deposit date is January 20, 2025, and its biological deposit number is CCTCC NO: M 2025187.

[0007] A second aspect of the present invention provides a composition comprising postbiotics and D-psicose; The mass ratio of the postbiotics to D-psicose is 60-100:0.1-0.4.

[0008] The postbiotics include inactivated Lactobacillus gasseri ( lactobacillus gasseri )co-1.

[0009] The third aspect of the present invention provides a method for preparing the above composition, comprising the step of mixing the postbiotics with D-psicose.

[0010] A fourth aspect of the present invention provides use of the above composition in preparing a product; The product has any one or more of the following effects: (a) Inhibit α-glucosidase activity; (b) regulating blood sugar concentration; (c) Treatment or adjunctive treatment of diabetes mellitus.

[0011] Through research, the present invention found that the combination of postbiotics and D-psicose can synergistically inhibit α-glucosidase. Further animal experiments have proved that it has the effect of inhibiting the increase of blood sugar, thereby playing a role in regulating the blood sugar concentration of the diabetic population.

[0012] In the present invention, the product can be food, medicine or common reagent for non-medical use.

[0013] Beneficial technical effects of one or more of the above technical solutions: The above technical solution achieves a significant improvement in the hypoglycemic effect by combining postbiotics with D-psicose. As a non-energy sweetener, D-psicose itself has the potential to prevent obesity and control blood sugar. However, its effect may be limited when used alone. The above technical solution combines Lactobacillus gasseri ( Lactobacillus gasseri) The postbiotics obtained from co-1 fermentation work synergistically with D-psicose to more effectively regulate blood sugar metabolism. In addition, the positive effect of postbiotics on intestinal health further enhances the overall blood sugar-lowering ability. Postbiotics improve the intestinal environment related to metabolic diseases by enhancing the intestinal barrier function and regulating the intestinal flora. This multi-level mechanism of action not only helps control blood sugar, but also improves the symptoms of prediabetes and effectively prevents or delays the development of diabetes.

[0014] In summary, through scientific design and optimization, the above technical scheme provides a postbiotic and composition that synergistically improves the blood sugar lowering ability of D-psicose, has a significant blood sugar lowering effect and broad application prospects, and provides an innovative solution for the prevention and treatment of diabetes and its pre-stages. BRIEF DESCRIPTION OF THE DRAWINGS

[0015] Figure 1 The inhibition rate (A) and IC50 (B) of D-psicose on α-glucosidase in the validation of the effect of the present invention.

[0016] Figure 2 The inhibition rate (A) and IC50 (B) of postbiotics on α-glucosidase in the efficacy verification of the present invention.

[0017] Figure 3 This is the inhibition curve of postbiotics and D-psicose on α-glucosidase in the effect verification of the present invention; wherein, P represents D-psicose; H represents postbiotics; LH represents the combined use of D-psicose and postbiotics.

[0018] Figure 4 This is a graph showing changes in blood sugar levels in rats of each group in the validation of the effects of the present invention.

[0019] Figure 5 This is a graph showing changes in the oral glucose tolerance levels of rats in each group in the validation of the effects of the present invention. DETAILED DESCRIPTION

[0020] It should be noted that the following detailed descriptions are exemplary and are intended to provide further explanation of the present invention. Unless otherwise specified, all technical and scientific terms used in the present invention have the same meanings as those commonly understood by those skilled in the art to which the present invention belongs.

[0021] It should be noted that the terms used herein are only for describing specific embodiments and are not intended to limit the exemplary embodiments of the present invention. As used herein, unless the context clearly indicates otherwise, the singular form is also intended to include the plural form. In addition, it should be understood that when the terms "comprising" and / or "including" are used in this specification, it indicates the presence of features, steps, operations, devices, components and / or combinations thereof.

[0022] The present invention is further explained by the following examples, but they are not intended to limit the present invention. It should be understood that these examples are only used to illustrate the present invention and are not intended to limit the scope of the present invention.

[0023] It should be noted that the following detailed descriptions are exemplary and are intended to provide further explanation of the present invention. Unless otherwise specified, all technical and scientific terms used in the present invention have the same meanings as those commonly understood by those skilled in the art to which the present invention belongs.

[0024] It should be noted that the terms used herein are only for describing specific embodiments and are not intended to limit the exemplary embodiments of the present invention. As used herein, unless the context clearly indicates otherwise, the singular form is also intended to include the plural form. In addition, it should be understood that when the terms "comprising" and / or "including" are used in this specification, it indicates the presence of features, steps, operations, devices, components and / or combinations thereof.

[0025] In a typical embodiment of the present invention, a postbiotic is provided for use in preparing a product that improves the blood sugar lowering ability of D-psicose; Wherein, the postbiotics include inactivated Lactobacillus gasseri ( lactobacillus gasseri )co-1.

[0026] The Lactobacillus gasseri ( lactobacillus gasseri )co-1, deposited in the China Center for Type Culture Collection (address: Wuhan University, Luojia Mountain, Wuchang, Wuhan City, Hubei Province), the deposit date is January 20, 2025, its biological deposit number is CCTCC NO: M 2025187, and its 16S rDNA sequence is shown in SEQ ID NO.1.

[0027] Furthermore, the glucose-lowering ability of D-psicose is specifically manifested in the inhibition of α-glucosidase activity.

[0028] In another specific embodiment of the present invention, a composition is provided, comprising postbiotics and D-psicose; The mass ratio of the postbiotics to D-psicose is 60-100:0.1-0.4.

[0029] The postbiotics include inactivated Lactobacillus gasseri ( lactobacillus gasseri )co-1.

[0030] Furthermore, the postbiotics are prepared by the following method: (1) the Lactobacillus gasseri ( lactobacillus gasseri ) co-1 was streaked into activation medium to obtain a pure strain; (2) picking a single colony of Lactobacillus gasseri obtained in step (1) and placing it in a first culture solution and culturing it at 35-37° C. for 14-20 hours to obtain a primary seed solution; (3) Inoculate the cultured primary seed solution into the second culture solution at an inoculation rate of 1-5% (preferably 2%). v / v ), incubate at 35-37°C (preferably 37°C) for 14-20 hours to obtain a secondary seed solution; (4) Inoculate the secondary seed solution into the third culture solution at an inoculation rate of 3-8% (preferably 5%). v / v ), at 35-37 ℃ (preferably 37 ℃), 100-150 r / min (preferably 100 r / min), the tank pressure is maintained at 0.05 MPa, and the culture is carried out for 5-6 hours; then the stirring speed is reduced to 50-100 r / min (preferably 80 r / min), the fermentation temperature is reduced to 35°C, the tank pressure is maintained at 0.05 MPa, the pH is adjusted to weak acidity (pH 6.5), and fermentation is carried out for 3-4 hours; then the fermentation temperature is reduced to 30℃, the tank pressure is increased to 0.1-0.12 MPa (preferably 0.1 Mpa), the pH is maintained at weak acidity (pH 6.5), and fermentation is continued for 4-5 hours; then the stirring speed and tank pressure are kept unchanged, the temperature is increased to 40-50 °C (preferably 45℃), glycerol is added to the fermentation broth at a volume of 0.2-0.5% (preferably 0.3%), and high temperature sterilization is carried out.

[0031] Wherein, in the step (1), the composition of the activation culture medium is as follows: fructose 1.0-2.0%, yeast peptone 1.0-2.0%, yeast extract powder 0.5-1.0%, beef extract powder 1.0-1.5%, sodium acetate 0.05-0.1%, triammonium citrate 0.05-0.1%, potassium dihydrogen phosphate 0.5-1.0%, agar powder 0.15-0.2%, and the pH is adjusted to weak acidity (pH 6.5).

[0032] In the step (2), the first culture solution has the following composition: 1.0-2.0% fructose, 1.0-2.0% yeast peptone, 0.5-1.0% yeast extract powder, 1.0-1.5% beef extract powder, 0.05-0.1% sodium acetate, 0.05-0.1% triammonium citrate, 0.5-1.0% potassium dihydrogen phosphate, and the pH is adjusted to weak acidity (pH 6.5).

[0033] In the step (3), the composition of the second culture solution is as follows: 1.0-1.5% fructooligosaccharide, 1.0-1.5% yam starch, 1.0-2.0% fructose, 1.0-2.0% yeast peptone, 0.5-1.0% yeast extract powder, 0.05-0.1% sodium acetate, 0.05-0.1% triammonium citrate, 0.5-1.0% potassium dihydrogen phosphate, and the pH is adjusted to weak acidity (pH 6.5).

[0034] In step (4), the composition of the third culture solution is as follows: 1.0-1.5% fructooligosaccharides, 1.0-1.5% corn starch, 0.5-1% tyrosine, 1.0-2.0% glucose, 1.0-2.0% yeast peptone, 0.5-1.0% yeast extract powder, 0.05-0.1% sodium acetate, 0.05-0.1% triammonium citrate, 0.5-1.0% potassium dihydrogen phosphate, and the pH is adjusted to weak acidity (pH 6.5).

[0035] Furthermore, in step (4), the high temperature sterilization may be performed by raising the temperature to 85°C and maintaining the temperature for 30 minutes for sterilization; further, the culture solution after high temperature sterilization is spray-dried to obtain the postbiotic powder.

[0036] In another specific embodiment of the present invention, a method for preparing the above composition is provided, the method comprising the step of mixing the postbiotics with D-psicose. Further, mixing in a three-dimensional mixer at 80-150 r / min (preferably 100 r / min) for 10-100 minutes (preferably 60 minutes).

[0037] In another specific embodiment of the present invention, there is provided the use of the above composition in preparing a product; The product has any one or more of the following effects: (a) Inhibit α-glucosidase activity; (b) regulating blood sugar concentration; (c) Treatment or adjunctive treatment of diabetes mellitus.

[0038] Through research, the present invention found that the combination of postbiotics and D-psicose can synergistically inhibit α-glucosidase. Further animal experiments have proved that it has the effect of inhibiting the increase of blood sugar, thereby playing a role in regulating the blood sugar concentration of the diabetic population.

[0039] In the present invention, the product can be food, medicine or common reagent for non-medical use.

[0040] The term "food" used in the present invention can be in any form that can be eaten, including ordinary food and special food. The special food includes health food and special medical formula food; and ordinary food is relative to special food, which is food suitable for everyone.

[0041] The medicine of the present invention may also contain commonly used carriers, carriers, excipients and diluents, etc. Moreover, according to the usual method, it can be made into oral preparations, external preparations, suppositories and sterile injection solutions in the form of powders, granules, suspensions, emulsions, syrups, sprays, etc.

[0042] The present invention is further explained by the following examples, but they are not intended to limit the present invention. It should be understood that these examples are only used to illustrate the present invention and are not intended to limit the scope of the present invention. In each example, the specific components of each culture medium are as follows: Activation culture medium: fructose 1.5%, yeast peptone 1.5%, yeast extract powder 1.0%, beef extract powder 1.5%, sodium acetate 0.05%, triammonium citrate 0.05%, potassium dihydrogen phosphate 0.5%, agar powder 0.2%, adjust pH to 6.5.

[0043] The composition of the first culture medium is as follows: 1.5% fructose, 2.0% yeast peptone, 0.5% yeast extract powder, 1.5% beef extract powder, 0.1% sodium acetate, 0.05% triammonium citrate, 0.5% potassium dihydrogen phosphate, and the pH is adjusted to 6.5.

[0044] The second culture medium: 1.5% fructooligosaccharide, 1.0% yam starch, 2.0% fructose, 2.0% yeast peptone, 1.0% yeast extract powder, 0.05% sodium acetate, 0.05% triammonium citrate, 0.5% potassium dihydrogen phosphate, adjust the pH to 6.5.

[0045] The third culture medium: 1.0% fructooligosaccharide, 1.5% corn starch, 0.5% tyrosine, 1.0% glucose, 2.0% yeast peptone, 0.5% yeast extract powder, 0.05% sodium acetate, 0.05% triammonium citrate, 0.5% potassium dihydrogen phosphate, adjust the pH to 6.5.

[0046] The “%” of the components in the above activation culture medium and the first to third culture solutions refers to the mass volume percentage, in units of g / mL.

[0047] Example 1 A method for preparing postbiotics comprises the following steps: Lactobacillus gasseri ( lactobacillus gasseri ) co-1 was streaked into the activation medium to obtain a pure strain; a single colony of Lactobacillus gasseri was selected and placed in the first culture medium at 37°C for 20 hours to obtain a primary seed solution; the primary seed solution was inoculated at a rate of 2% ( v / v ) was inoculated into the second culture solution and cultured at 37°C for 20 hours to obtain the secondary seed solution.

[0048] According to the inoculation rate of 5% ( v / v ) inoculation amount of the Lactobacillus gasseri secondary seed liquid was inoculated into a fermentation tank containing a sterilized third culture solution, and cultured at 37°C, 100 r / min, the tank pressure was maintained at 0.05 MPa, and the culture was continued for 6 hours; then the stirring speed was reduced to 80 r / min, the fermentation temperature was reduced to 35°C, the tank pressure was maintained at 0.05 MPa, the pH was adjusted to 6.5 with ammonia water, and fermented for 4 hours; then the fermentation temperature was reduced to 30°C, the stirring speed remained unchanged, the tank pressure was increased to 0.1 MPa, the pH was adjusted to 6.5 with ammonia water, and fermented for 5 hours; then the stirring speed was maintained unchanged, the temperature was increased to 45°C, 0.3% glycerol by volume of the fermentation solution was added to the fermentation tank, the temperature was increased to 85°C, maintained for 30 min, and then spray-dried.

[0049] Example 2 Lactobacillus gasseri ( lactobacillus gasseri ) co-1 was streaked into the activation medium to obtain a pure strain; a single colony of Lactobacillus gasseri was selected and placed in the first culture medium at 37°C for 20 hours to obtain a primary seed solution; the primary seed solution was inoculated at a rate of 2% ( v / v ) was inoculated into the second culture solution and cultured at 37°C for 20 hours to obtain the secondary seed solution.

[0050] According to the inoculation rate of 5% ( v / v ) inoculation amount of the Lactobacillus gasseri secondary seed liquid was inoculated into a fermentation tank containing a sterilized third culture solution, and cultured at 37°C, 100 r / min, the tank pressure was maintained at 0.05 MPa, and the culture was continued for 6 hours; then the stirring speed was reduced to 80 r / min, the fermentation temperature was reduced to 35°C, the tank pressure was maintained at 0.05 MPa, the pH was adjusted to 6.5 with ammonia water, and fermented for 4 hours; then the fermentation temperature was reduced to 30°C, the stirring speed remained unchanged, the tank pressure was increased to 0.1 MPa, the pH was adjusted to 6.5 with ammonia water, and fermented for 5 hours; then the stirring speed was maintained unchanged, the temperature was increased to 45°C, 0.3% glycerol by volume of the fermentation solution was added to the fermentation tank, the temperature was increased to 85°C, maintained for 30 min, and then spray-dried.

[0051] 2000 g of the above postbiotics were mixed with 8 g of D-psicose, and mixed in a three-dimensional mixer at 100 r / min for 60 minutes to obtain a postbiotic D-psicose composition.

[0052] Effect verification The composition for improving the hypoglycemic effect is verified by the following verification method: Diabetes is a chronic endocrine disorder characterized by hyperglycemia. The main way to treat diabetes is to reduce postprandial hyperglycemia. α-Glucosidase inhibitors can delay or inhibit the absorption of glucose in the intestine by inhibiting the catalytic degradation of polysaccharides into monosaccharides by α-glucosidase in the small intestine, thereby effectively reducing postprandial hyperglycemia. As the first choice for the treatment of type 2 diabetes, α-glucosidase inhibitors have been widely used clinically. Therefore, when evaluating the hypoglycemic effect of a certain component, it is usually evaluated by its inhibitory effect on α-glucosidase. The present invention uses p-nitrophenyl α-D-glucoside (α-PNPG) as a substrate, which is hydrolyzed under the action of α-glucosidase to generate p-nitrophenol (PNP), and PNP has a specific absorption peak at 405nm. Based on this principle, we evaluated the inhibitory effect of the sample to be tested on the activity of α-glucosidase. The specific determination process is as follows, and the specific volume of reagent added is shown in Table 1.

[0053] 200 μL of sample solution with different concentrations and 200 μL of α-glucosidase solution (1.5 U / mL) were taken, mixed evenly and incubated in a 37℃ water bath for 5 minutes. 200 μL of PNPG solution (2.5 mmol / L) was added, mixed evenly and continued to incubate in a 37℃ water bath for 15 minutes. 800 μL of Na2CO3 solution (0.2 mol / L) was added to terminate the reaction and stop the hydrolysis reaction of α-glucosidase. According to the specific absorption principle of p-nitrophenol (PNP) at 405 nm, 160 μL of the reaction stop solution was taken into a 96-well plate, and the absorbance (OD value) at a wavelength of 405 nm was measured in an ELISA reader. The amount of PNP produced by the hydrolysis of α-PNPG by α-glucosidase after adding D-psicose and postbiotics was detected, and the inhibition rate was calculated to evaluate the effect of D-psicose and postbiotics on the activity of α-glucosidase. Each sample was measured three times in parallel and the average value was taken to improve the accuracy and reliability of the data.

[0054]

[0055] Table 1 α-glucosidase inhibition rate system configuration

[0056] (1) According to the above-mentioned α-glucosidase inhibitory activity assay method, the effect of D-psicose on α-glucosidase activity at concentrations of 10, 50, 100, 200, 300, and 500 μg / mL was determined. The results are as follows: Figure 1 As shown in A, it can be seen that the inhibitory effect of D-psicose on α-glucosidase increases with the increase of concentration. The D-psicose concentration (X) is taken logarithm, and a linear regression equation is established between it and the inhibition rate (Y) to calculate the IC50 value. Figure 1 As shown in B, the IC50 value of α-glucosidase for D-psicose is 286.1 μg / mL.

[0057] (2) Similarly, the above-mentioned α-glucosidase inhibitory activity assay method was used to determine the effects of postbiotics on α-glucosidase activity at concentrations of 20, 40, 60, 80, 150, and 200 mg / mL. The results are shown in Table 1. Figure 2 As shown in A, it can be seen that the inhibitory effect of postbiotics on α-glucosidase increases with the increase of concentration. The logarithm of the postbiotic addition concentration (X) is taken, and a linear regression equation is established between the concentration and the inhibition rate (Y) to calculate the IC50 value. Figure 2 As shown in B, the IC50 value of α-glucosidase of postbiotics is 74.38 mg / mL.

[0058] (3) According to the above method, the inhibitory activity of postbiotics and D-psicose on α-glucosidase was determined. When postbiotics and D-psicose were used in combination, the final concentrations of D-psicose were 100, 200 and 400 μg / mL, and the final concentrations of postbiotics were 60, 80 and 100 mg / mL, respectively. Nine groups of different concentrations of postbiotics and D-psicose were set up, and the effects of different concentrations of postbiotics and D-psicose on α-glucosidase activity were determined according to the above method. The combination index (CI) was calculated by the Chou-Talalay method to evaluate the interaction between postbiotics and D-psicose. The CI value of the inhibitory effect of postbiotics and D-psicose on α-glucosidase was calculated by CompuSyn 1.0 software. Where CI < 1 indicates that there is a synergistic effect between postbiotics and D-psicose, CI = 1 indicates that there is an additive effect between postbiotics and D-psicose, and CI > 1 indicates that there is an antagonistic effect between postbiotics and D-psicose. The results are shown in Table 2. The Fa diagram obtained by the software CompuSyn 1.0 is shown in Figure 3 As shown, it can be seen from the results that the CI values ​​of different concentration combinations of postbiotics and D-psicose are all less than 1, indicating that there is a synergistic effect between postbiotics and D-psicose in the inhibition of α-glucosidase.

[0059] Table 2 Inhibition of α-glucosidase activity by combined use of D-psicose and postbiotics

[0060] The effect of the composition on regulating blood sugar in diabetic rats is verified by the following method: SD rats with an initial body weight of 180-200 g were selected and fed adaptively for 1 week. After the blood sugar test was normal, 6 rats were selected as the normal control group, and the other rats were fasted but not watered for 24 hours before modeling. The animals in the modeling group were given STZ 39 mg / kg by tail vein injection, and the control group was given an equal volume of citrate buffer. After 72 hours, blood sugar and urine sugar were measured, and animals with blood sugar concentrations >16.7 mmol / L were considered to have successfully modeled. The diabetic rats were divided into 5 groups by random sampling. The model group (equal volume of normal saline), Example 1 group (100 mg / kg) and Example 2 group (100 mg / kg), 6 rats in each group, were gavaged once a day for 6 consecutive weeks. During the feeding process, the tail blood of the rats was collected weekly to measure the fasting blood sugar (FBG) level. After five weeks of feeding, the oral glucose tolerance of the rats was measured.

[0061] As expected, compared with the control Wistar rats, the FBG levels of the rats in Example 1 and Example 2 groups were decreased at all time points, with a significant decrease in the Example 2 group ( Figure 4 ), further testing oral glucose tolerance, the increase in glucose concentrations in Example 1 and Example 2 groups at 2 hours and 3 hours was significantly lower than that in the model group, especially in Example 2 group ( Figure 5 ).

[0062] Nucleotide sequence information involved in this application: Lactobacillus gasseri ( lactobacillus gasseri )co-1 16S rDNA sequence: The above embodiments are only for illustrating the technical concept and features of the present invention, and their purpose is to enable people familiar with the technology to understand the content of the present invention and implement it accordingly, and they cannot be used to limit the protection scope of the present invention. Any equivalent changes or modifications made according to the spirit of the present invention should be included in the protection scope of the present invention.

Claims

1. Application of postbiotics in the preparation of products that improve the blood sugar-lowering ability of D-psicose; in, The postbiotics include inactivated Lactobacillus gasseri ( lactobacillus gasseri )co-1; The Lactobacillus gasseri ( lactobacillus gasseri )co-1, deposited in China Center for Type Culture Collection, the preservation date is January 20, 2025, and its biological preservation number is CCTCC NO: M 2025187.

2. The use according to claim 1, characterized in that The glucose-lowering ability of D-psicose is specifically manifested in the inhibition of α-glucosidase activity.

3. A composition, characterized in that The composition comprises postbiotics and D-psicose; the mass ratio of the postbiotics to D-psicose is 60-100:0.1-0.4; The postbiotics include the inactivated Lactobacillus gasseri used in the application as claimed in claim 1 ( lactobacillus gasseri )co-1.

4. The composition according to claim 3, characterized in that The postbiotics are prepared by the following method: (1) the Lactobacillus gasseri ( lactobacillus gasseri ) co-1 was streaked into activation medium to obtain a pure strain; (2) picking a single colony of Lactobacillus gasseri obtained in step (1) and placing it in a first culture solution and culturing it at 35-37° C. for 14-20 hours to obtain a primary seed solution; (3) inoculating the cultured primary seed solution into the second culture solution at an inoculation amount of 1-5%, and culturing at 35-37° C. for 14-20 hours to obtain a secondary seed solution; (4) The secondary seed liquid is inoculated into the third culture liquid with an inoculation amount of 3-8%, and the culture is carried out at 35-37°C, 100-150 r / min, and the tank pressure is maintained at 0.05 MPa for 5-6 hours; then the stirring speed is reduced to 50-100 r / min, the fermentation temperature is reduced to 35°C, the tank pressure is maintained at 0.05 MPa, the pH is adjusted to weak acidity, and fermentation is carried out for 3-4 hours; then the fermentation temperature is reduced to 30°C, the tank pressure is increased to 0.1-0.12 MPa, the pH is maintained at weak acidity, and fermentation is continued for 4-5 hours; then the stirring speed and tank pressure are kept unchanged, the temperature is increased to 40-50°C, glycerol is added to the fermentation liquid at a volume of 0.2-0.5% of the fermentation liquid, and high-temperature sterilization is carried out.

5. The composition according to claim 4, characterized in that In step (1), the activation culture medium is composed of: 1.0%-2.0% D-psicose, 1.0%-2.0% yeast peptone, 0.5%-1.0% yeast extract powder, 1.0%-1.5% beef extract powder, 0.05-0.1% sodium acetate, 0.05-0.1% triammonium citrate, 0.5-1.0% potassium dihydrogen phosphate, 0.15-0.2% agar powder, and the pH is adjusted to weak acidity; In step (2), the first culture solution comprises: 1.0%-2.0% D-psicose, 1.0%-2.0% yeast peptone, 0.5%-1.0% yeast extract powder, 1.0%-1.5% beef extract powder, 0.05%-0.1% sodium acetate, 0.05%-0.1% triammonium citrate, 0.5%-1.0% potassium dihydrogen phosphate, and the pH is adjusted to weak acidity; In step (3), the second culture solution comprises the following: 1.0-1.5% fructooligosaccharide, 1.0-1.5% yam starch, 1.0-2.0% fructose, 1.0-2.0% yeast peptone, 0.5-1.0% yeast extract powder, 0.05-0.1% sodium acetate, 0.05-0.1% triammonium citrate, 0.5-1.0% potassium dihydrogen phosphate, and the pH is adjusted to weak acidity; In step (4), the composition of the third culture solution is as follows: 1.0-1.5% fructooligosaccharide, 1.0-1.5% corn starch, 0.5-1% tyrosine, 1.0-2.0% glucose, 1.0-2.0% yeast peptone, 0.5-1.0% yeast extract powder, 0.05-0.1% sodium acetate, 0.05-0.1% triammonium citrate, 0.5-1.0% potassium dihydrogen phosphate, and the pH is adjusted to weak acidity.

6. The composition according to claim 4, characterized in that In step (4), the high temperature sterilization is specifically performed by raising the temperature to 85°C and maintaining it for 30 minutes for sterilization.

7. The composition according to claim 6, characterized in that In the step (4), the culture solution sterilized at high temperature is spray-dried to obtain the postbiotic powder.

8. A method for preparing a composition according to any one of claims 3 to 7, characterized in that: The preparation method includes the step of mixing the postbiotics with D-psicose.

9. Use of the composition according to any one of claims 3 to 7 in preparing a product; The product has any one or more of the following effects: (a) Inhibit α-glucosidase activity; (b) regulating blood sugar concentration; (c) Treatment or adjunctive treatment of diabetes mellitus.

10. The use according to claim 9, characterized in that The product is food, medicine or common reagent for non-medical use.

Images